Remepy

Pioneering hybrid drugs by combining pharmaceuticals with targeted digital interventions.

Health Tech & Life Sciences
Active
Series A New York, United States Founded 2021
Last updated 2026-11-02
Total raised
$62.0M
Last: A Round 2026-08
Stage
Series A
Founded
2021
Headcount
80
HQ
New York, United States
Sector
Health Tech & Life Sciences

About

Remepy is an Israeli startup pioneering a new category of therapy called "hybrid drugs." These drugs combine traditional pharmaceuticals with targeted digital interventions delivered via a mobile application. The company's mission is to deliver more personalized, adaptive, and effective care by uniting biology, behavior, and technology to help patients heal. Remepy's digital molecules are designed to trigger physiological effects through the brain, enhancing the effectiveness of traditional drugs. The company is initially targeting Parkinson's Disease with its Hybridopa product, and also exploring applications in neurodegenerative diseases, cancer, autoimmune diseases, and degenerative eye diseases.

Funding history · 4 rounds · $62.0M total

4 events/rounds · $62.0M Total Funding: $62.0M in Private Equity

Offices

New York, United States · HQ / main office

Q&A

What is Remepy's core mission?
Remepy is an Israeli startup focused on pioneering "hybrid drugs" that combine traditional pharmaceuticals with targeted digital interventions delivered via a mobile application. Their mission is to provide more personalized, adaptive, and effective care by integrating biology, behavior, and technology.
When was Remepy founded?
Remepy was founded in December 2021.
What is Remepy's total funding to date?
Remepy has raised a total of $62,000,000 USD.
When did Remepy complete its most recent funding round?
Remepy completed an A Round in August 2026, raising $36,000,000 USD.
Which investors participated in Remepy's Seed round in May 2024?
Remepy raised $10,000,000 USD in a Seed round in May 2024, with NFX and Vine Ventures as lead investors.
What is Remepy's initial target disease for its Hybridopa product?
Remepy is initially targeting Parkinson's Disease with its Hybridopa product.
Who are the co-CEOs of Remepy?
Dr. Michal Tsur and Or Shoval are the co-CEOs of Remepy.

Team · 14

Dr. Michal Tsur
Founder · Co-CEO
Or Shoval
Founder · Co-CEO
Prof. Amir Amedi
Founder · Chief Scientific Officer
Eran Etam
Founder · Chief Technology Officer
Dr. Shahar Shelly
Founder · founders
Dr. Nira Saporta
Chief Therapeutics Officer
Shai Erlich, MD, PhD
Chief Clinical Dev. Officer
Renan Gutman
Chief Product Officer
Eran Harary, MD
Chief Medical Officer
Nora Siperman
Chief Financial Officer
Ofer Tur-Sinai
General Counsel
Lisa Bennett
Chief Marketing Officer
Naftali Bennett
board
Dr. Danny Bar Zohar
Merck's Global Head of R&D

Sectors & technology

Primary sector
Health Tech & Life Sciences
Technologies
Target customers
Business model
B2BB2B2C

Highlights

Patents

Tags

digital-healthcaresaasdrug-discoverydrug-developmentpharmaceuticalsbiotechnologyhealth-techartificial-intelligence
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websiteremepy.com/
LinkedInlinkedin.com/company/82435157

Identifiers & details

Founded2021-12
Employees (exact)80

Radar intelligence

Patents

EPO3

Publications (Crossref)

Works2

GitHub

Top reposresearch-pages, flutter-plugins, better_player_plus, flutter_packages, betterplayer

App Store

AppRatingRatings
TGCT & Me

Web history (Wayback)

Domainremepy.com

Certificate / subdomain footprint

Subdomains9

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)516671476
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2022-08-29
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2025
Active charges / liens0
Registry events2 — charge (2)
Registered addressתובל 40 רמת גן

Recent registry events

DateEvent
2025-12-31רישום שעבוד
2026-05-13סילוק שעבוד